Overview

EFfect of Ferric Carboxymaltose on exercIse CApacity and Cardiac Function in Patients With Iron deficiencY and Chronic Heart Failure

Status:
Terminated

Trial end date:
2011-01-01

Target enrollment:

Participant gender:

Summary

This study is designed to assess, relative to placebo, the effects on the evolution of exercise capacity and symptomatic status of the addition of iron treatment with FCM (ferric carboxymaltose) to the basic regimen of ambulatory patients with stable symptomatic chronic CHF (congestive heart failure) and iron deficiency.

Phase:

Phase 3

Details

Lead Sponsor:

Vifor Inc.
Vifor Pharma

Collaborator:

Socar Research SA

Treatments:

Ferric Compounds
Iron